Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma (vol 11, e006802, 2023)

被引:0
|
作者
Gaissler, A.
Bochem, J.
Spreuer, J.
机构
关键词
D O I
10.1136/jitc-2023-006802corr1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:1
相关论文
共 4 条
  • [1] Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
    Gaissler, Andrea
    Bochem, Jonas
    Spreuer, Janine
    Ottmann, Shannon
    Martens, Alexander
    Amaral, Teresa
    Wagner, Nikolaus Benjamin
    Claassen, Manfred
    Meier, Friedegund
    Terheyden, Patrick
    Garbe, Claus
    Eigentler, Thomas
    Weide, Benjamin
    Pawelec, Graham
    Wistuba-Hamprecht, Kilian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [2] Monocyte subpopulations and myeloid-derived suppressor cells in peripheral blood of cancer patients receiving immune checkpoint inhibition-based treatment
    Peischl, C.
    Preusser, M.
    Berghoff, A. S. S.
    Fendl, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S560 - S560
  • [4] Increased frequencies of CD11b+CD33+CD14+HLA-DRlow myeloid-derived suppressor cells are an early event in melanoma patients
    Rudolph, Berenice M.
    Loquai, Carmen
    Gerwe, Alexander
    Bacher, Nicole
    Steinbrink, Kerstin
    Grabbe, Stephan
    Tuettenberg, Andrea
    EXPERIMENTAL DERMATOLOGY, 2014, 23 (03) : 202 - 204